La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Ayala Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Ayala Pharmaceuticals..

Ayala Pharmaceuticals (OTC:ADXS) Azioni, Catena delle Opzioni

Advaxis

Ayala Pharmaceuticals Inc is a clinical-stage oncology company whose primary clinical assets currently include aspacytarabine (BST-236), a novel proprietary anti-metabolite for first-line treatment in unfit acute myeloid leukemia (AML). BST-236 is a novel prodrug of cytarabine, enabling the delivery of high cytarabine doses with reduced systemic toxicity, creating a potential new backbone for AML combination regimens. It believes that its novel product candidates if approved, have the potential to transform treatment outcomes for patients suffering from solid and hematological cancers. These efforts are primarily focused on the development of ADXS-504, an Lm-based therapy for early-stage prostate cancer.

&ndash; Immunome entered into a definitive asset purchase agreement with Ayala to acquire AL102 earlier this month &ndash;

Biotech

News

General

ADXS

IMNM

Immunome Recognizes Ayala Pharmaceuticals' Announced Completion Of Enrollment In Phase 3 RINGSIDE Study For AL102 In Desmoid Tumors

Ladenburg Thalmann analyst Ahu Demir downgrades Ayala Pharmaceuticals (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ADXS#OTC">ADXS</a>) from Buy to Neutral.

Downgrades

Analyst Ratings

Ladenburg Thalmann Downgrades Ayala Pharmaceuticals to Neutral

<h3>Upgrades</h3>
Alliance Global Partners upgraded the previous rating for KNOT Offshore Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNOP#NYSE">KNOP</a>) from Neutral to Buy. KNOT Offshore Partners earned $0.04 in the first quarter, compared to $0.79 in the year-ago quarter. The stock has a 52-week-high of $18.67 and a 52-week-low of $4.28. At the end of the last trading period, KNOT Offshore Partners closed at $4.80. 
Ladenburg Thalmann upgraded the previous rating for Advaxis Inc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ADXS#OTC">ADXS</a>) from Neutral to Buy. The stock has a 52-week-high of $7.20 and a 52-week-low of $0.65. At the end of the last trading period, Advaxis closed at $0.85. 
For ChargePoint Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>), B of A Securities upgraded the previous rating of Neutral to Buy. ChargePoint Hldgs earned $0.13 in the fourth quarter, compared to $0.17 in the year-ago quarter. The current stock performance of ChargePoint Hldgs shows a 52-week-high of $19.92 and a 52-week-low of $7.82. Moreover, at the end of the last trading period, the closing price was at $8.49. 
For Elevation Oncology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>), SVB Securities upgraded the previous rating of Market Perform to Outperform. For the first quarter, Elevation Oncology had an EPS of $0.50, compared to year-ago quarter EPS of $0.74. The stock has a 52-week-high of $5.89 and a 52-week-low of $0.72. At the end of the last trading period, Elevation Oncology closed at $5.02. 
According to Vertical Research, the prior rating for Heico Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>) was changed from Hold to Buy. For the second quarter, Heico had an EPS of $0.76, compared to year-ago quarter EPS of $0.62. The current stock performance of Heico shows a 52-week-high of $180.59 and a 52-week-low of $127.17. Moreover, at the end of the last trading period, the closing price was at $159.30. 
According to Jefferies, the prior rating for Ford Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) was changed from Hold to Buy. Ford Motor earned $0.63 in the first quarter, compared to $0.38 in the year-ago quarter. The stock has a 52-week-high of $16.68 and a 52-week-low of $10.62. At the end of the last trading period, Ford Motor closed at $12.09. 
Roth MKM upgraded the previous rating for Boston Beer Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) from Neutral to Buy. Boston Beer Co earned $0.73 in the first quarter, compared to $0.16 in the year-ago quarter. The stock has a 52-week-high of $420.50 and a 52-week-low of $287.01. At the end of the last trading period, Boston Beer Co closed at $317.85. 
For Constellation Brands Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>), Roth MKM upgraded the previous rating of Neutral to Buy. For the fourth quarter, Constellation Brands had an EPS of $1.98, compared to year-ago quarter EPS of $2.37. At the moment, the stock has a 52-week-high of $261.23 and a 52-week-low of $208.12. Constellation Brands closed at $232.88 at the end of the last trading period. 
For Equitrans Midstream Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETRN#NYSE">ETRN</a>), RBC Capital upgraded the previous rating of Sector Perform to Outperform. For the first quarter, Equitrans Midstream had an EPS of $0.22, compared to year-ago quarter EPS of $0.14. The current stock performance of Equitrans Midstream shows a 52-week-high of $9.89 and a 52-week-low of $4.60. Moreover, at the end of the last trading period, the closing price was at $6.09. 
For Coinbase Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), Atlantic Equities upgraded the previous rating of Neutral to Overweight. For the first quarter, Coinbase Glb had an EPS of $0.34, compared to year-ago quarter EPS of $1.98. At the moment, the stock has a 52-week-high of $116.30 and a 52-week-low of $31.55. Coinbase Glb closed at $56.92 at the end of the last trading period. 
According to BMO Capital, the prior rating for Alliant Energy Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNT#NASDAQ">LNT</a>) was changed from Market Perform to Outperform. In the first quarter, Alliant Energy showed an EPS of $0.65, compared to $0.77 from the year-ago quarter. The current stock performance of Alliant Energy shows a 52-week-high of $64.59 and a 52-week-low of $47.23. Moreover, at the end of the last trading period, the closing price was at $50.97. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
<h3>Downgrades</h3>
According to Macquarie, the prior rating for NeoGames SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGMS#NASDAQ">NGMS</a>) was changed from Outperform to Neutral. In the first quarter, NeoGames showed an EPS of $0.20, compared to $0.03 from the year-ago quarter. The current stock performance of NeoGames shows a 52-week-high of $27.77 and a 52-week-low of $10.85. Moreover, at the end of the last trading period, the closing price was at $27.27. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
<h3>Initiations</h3>
With a Buy rating, Jefferies initiated coverage on Acelyrin Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRN#NASDAQ">SLRN</a>). The price target seems to have been set at $31.00 for Acelyrin. The stock has a 52-week-high of $25.84 and a 52-week-low of $19.06. At the end of the last trading period, Acelyrin closed at $19.27. 
With an Outperform rating, Northland Capital Markets initiated coverage on Tigo Energy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYGO#NASDAQ">TYGO</a>). The price target seems to have been set at $20.00 for Tigo Energy. The stock has a 52-week-high of $21.33 and a 52-week-low of $10.40. At the end of the last trading period, Tigo Energy closed at $10.76. 
Craig-Hallum initiated coverage on Heritage Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HGBL#NASDAQ">HGBL</a>) with a Buy rating. The price target for Heritage Glb is set to $6.00. Heritage Glb earned $0.08 in the first quarter, compared to $0.02 in the year-ago quarter. The stock has a 52-week-high of $3.81 and a 52-week-low of $1.15. At the end of the last trading period, Heritage Glb closed at $3.81. 
UBS initiated coverage on Kenvue Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) with a Neutral rating. The price target for Kenvue is set to $28.00. At the moment, the stock has a 52-week-high of $27.80 and a 52-week-low of $25.25. Kenvue closed at $26.30 at the end of the last trading period. 
RBC Capital initiated coverage on Viridian Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) with an Outperform rating. The price target for Viridian Therapeutics is set to $44.00. Viridian Therapeutics earned $1.61 in the first quarter, compared to $0.98 in the year-ago quarter. At the moment, the stock has a 52-week-high of $39.00 and a 52-week-low of $9.84. Viridian Therapeutics closed at $23.73 at the end of the last trading period. 
With a Buy rating, B of A Securities initiated coverage on Kenvue Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>). The price target seems to have been set at $30.00 for Kenvue. The current stock performance of Kenvue shows a 52-week-high of $27.80 and a 52-week-low of $25.25. Moreover, at the end of the last trading period, the closing price was at $26.30. 
With a Equal-Weight rating, Morgan Stanley initiated coverage on Steris PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>). The price target seems to have been set at $206.00 for Steris. In the fourth quarter, Steris showed an EPS of $2.30, compared to $2.04 from the year-ago quarter. The current stock performance of Steris shows a 52-week-high of $235.95 and a 52-week-low of $159.88. Moreover, at the end of the last trading period, the closing price was at $200.44. 
Morgan Stanley initiated coverage on The Cooper Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COO#NYSE">COO</a>) with a Equal-Weight rating. The price target for Cooper Companies is set to $410.00. Cooper Companies earned $2.90 in the first quarter, compared to $3.24 in the year-ago quarter. The current stock performance of Cooper Companies shows a 52-week-high of $395.20 and a 52-week-low of $244.53. Moreover, at the end of the last trading period, the closing price was at $369.39. 
RBC Capital initiated coverage on Kenvue Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) with an Outperform rating. The price target for Kenvue is set to $29.00. The stock has a 52-week-high of $27.80 and a 52-week-low of $25.25. At the end of the last trading period, Kenvue closed at $26.30. 
With a Buy rating, Needham initiated coverage on Confluent Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>). The price target seems to have been set at $35.00 for Confluent. Confluent earned $0.09 in the first quarter, compared to $0.19 in the year-ago quarter. The current stock performance of Confluent shows a 52-week-high of $34.39 and a 52-week-low of $16.60. Moreover, at the end of the last trading period, the closing price was at $28.71. 
William Blair initiated coverage on Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with an Outperform rating. In the first quarter, Vertex Pharmaceuticals showed an EPS of $3.05, compared to $3.52 from the year-ago quarter. The stock has a 52-week-high of $354.46 and a 52-week-low of $243.25. At the end of the last trading period, Vertex Pharmaceuticals closed at $329.99. 
TD Cowen initiated coverage on Acelyrin Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRN#NASDAQ">SLRN</a>) with an Outperform rating. At the moment, the stock has a 52-week-high of $25.84 and a 52-week-low of $19.06. Acelyrin closed at $19.27 at the end of the last trading period. 
With a Neutral rating, Exane BNP Paribas initiated coverage on Kenvue Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>). The price target seems to have been set at $28.00 for Kenvue. At the moment, the stock has a 52-week-high of $27.80 and a 52-week-low of $25.25. Kenvue closed at $26.30 at the end of the last trading period. 
Citigroup initiated coverage on Kenvue Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) with a Neutral rating. The price target for Kenvue is set to $28.00. At the moment, the stock has a 52-week-high of $27.80 and a 52-week-low of $25.25. Kenvue closed at $26.30 at the end of the last trading period. 
With an Overweight rating, Piper Sandler initiated coverage on Acelyrin Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRN#NASDAQ">SLRN</a>). The price target seems to have been set at $68.00 for Acelyrin. The stock has a 52-week-high of $25.84 and a 52-week-low of $19.06. At the end of the last trading period, Acelyrin closed at $19.27. 
With a Equal-Weight rating, Barclays initiated coverage on Paylocity Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NASDAQ">PCTY</a>). The price target seems to have been set at $199.00 for Paylocity Holding. For the third quarter, Paylocity Holding had an EPS of $1.74, compared to year-ago quarter EPS of $1.22. The stock has a 52-week-high of $275.48 and a 52-week-low of $152.12. At the end of the last trading period, Paylocity Holding closed at $172.61. 
With a Hold rating, Deutsche Bank initiated coverage on Kenvue Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>). The price target seems to have been set at $27.00 for Kenvue. At the moment, the stock has a 52-week-high of $27.80 and a 52-week-low of $25.25. Kenvue closed at $26.30 at the end of the last trading period. 
Goldman Sachs initiated coverage on Kenvue Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) with a Neutral rating. The price target for Kenvue is set to $29.00. At the moment, the stock has a 52-week-high of $27.80 and a 52-week-low of $25.25. Kenvue closed at $26.30 at the end of the last trading period. 
With an Overweight rating, JP Morgan initiated coverage on Kenvue Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>). The price target seems to have been set at $29.00 for Kenvue. The stock has a 52-week-high of $27.80 and a 52-week-low of $25.25. At the end of the last trading period, Kenvue closed at $26.30. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Upgrades

Initiation

Intraday Update

CFLT

CHPT

COIN

ELEV

ETRN

HGBL

KNOP

KVUE

NGMS

PCTY

SLRN

TYGO

VRDN

VRTX

Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023

Ladenburg Thalmann analyst Ahu Demir upgrades Advaxis (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ADXS#OTC">ADXS</a>) from Neutral to Buy and announces $4 price target.

Price Target

Ladenburg Thalmann Upgrades Advaxis to Buy, Announces $4 Price Target

<ul>
<li>Ayala Pharmaceuticals Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ayla#NASDAQ">AYLA</a>) and&nbsp;Advaxis Inc&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/adxs#OTC">ADXS</a>) have announced a merger agreement.&nbsp;</li>
<li>The merger would result in a combined company focusing predominantly on developing and commercializing Ayala&#39;s lead program AL102 to treat desmoid tumors and Advaxis&#39;s candidate ADXS-504 in development for prostate cancer.</li>
<li>Ayala&#39;s lead candidate, AL102, is currently being investigated in the Phase 2/3 RINGSIDE study in desmoid tumors.&nbsp;</li>
<li>The combined company has the cash to advance the combined portfolio through key milestones in 2023.</li>
<li>Each Ayala share will be converted into the right to receive Advaxis shares. Combined Company to Seek Uplisting to Nasdaq.</li>
<li>Upon completion of the merger, Ayala stockholders will own approximately 62.5% of the combined company, and Advaxis stockholders will own approximately 37.5%.</li>
<li>The board of directors of the combined company is expected to consist of seven members: two designated by Advaxis, four by Ayala, and Kenneth Berlin, President &amp; CEO of Advaxis.</li>
<li>The management will include - Kenneth Berlin, President, CEO &amp; Director; Andres Gutierrez, current Chief Medical Officer of Advaxis; Igor Gitelman, Interim Chief Financial Officer of Advaxis.&nbsp;</li>
<li>Roni Mamluk, Founder &amp; CEO of Ayala, and Yossi Maimon, CFO of Ayala, will resign.&nbsp;</li>
<li>Gary Gordon, Chief Medical Officer of Ayala, will also resign but is expected to continue in an advisory role for some time.&nbsp;</li>
<li>Price Action:&nbsp;AYLA shares are down 28.70% at $0.65 on the last check Wednesday.</li>
</ul>

Penny Stocks

Health Care

Movers

Trading Ideas

AYLA

Ayala Pharmaceuticals and Advaxis Agree To Combine, Expect Uplisting On NASDAQ

Ayala Pharmaceuticals, Inc. (Nasdaq: <a class="ticker" href="https://www.benzinga.com/stock/ayla#Nasdaq">AYLA</a>) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers and Advaxis, Inc. (OTCQX: <a class="ticker" href="https://www.benzinga.com/stock/adxs#OTCQX">ADXS</a>) (Advaxis), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes, today announced that they have entered into a definitive merger agreement. The merger would result in a combined company that will focus predominantly on the development and commercialization of Ayala's lead program AL102 for the treatment of desmoid tumors and Advaxis's candidate ADXS-504 in development for prostate cancer.
Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, said, "Advaxis took a thorough approach in our quest to find the right partner with the right products. This merger is expected to enhance Advaxis's portfolio of clinical assets, with Ayala's proprietary gamma secretase inhibitors that are being developed as targeted therapies for rare and aggressive tumors. Ayala's lead candidate, AL102, is currently being investigated in the Phase 2/3 RINGSIDE study in desmoid tumors, which we believe will accelerate the stage of product development for the combined company dramatically. We are particularly excited about very promising interim data from RINGSIDE, which showed that AL102 monotherapy had meaningful anti-tumor activity with tumor shrinkage in the majority of patients that appeared to be deepening over time. The combined management team has extensive commercial and R&amp;D experience, and we believe we have the cash to advance the combined portfolio through key milestones in 2023, including longer-term data from Part A of RINGSIDE, clarity on the registration path for AL101 in recurrent/metastatic adenoid cystic carcinoma (ACC) and initial clinical and PSA data from the Phase 1 trial of ADXS-504 in prostate cancer. We believe that this transaction will also help drive our efforts to return to a Nasdaq listing and enhance our ability to access capital."  
Roni Mamluk, Ph.D., President and Chief Executive Officer of Ayala commented, "We are pleased to announce the proposed merger with Advaxis, which is expected to provide our pipeline and AL102 with additional financial resources as well as additional infrastructure in the U.S. The two companies have a shared mission to develop innovative therapies to improve the lives of patients with cancer and I believe we have found a good partner to advance our pipeline and create value for our stakeholders."
Additional Transaction Details
Subject to the terms and conditions of the merger agreement, at the closing of the merger, each outstanding share of Ayala common stock will be converted into the right to receive shares of common stock of Advaxis based on the exchange ratio set forth in the merger agreement. Upon completion of the merger, Ayala stockholders will own approximately 62.5% of the combined company's outstanding common stock and Advaxis stockholders will own approximately 37.5%, subject to the terms of the merger agreement. Advaxis will, at the effective time of the merger, assume the outstanding restricted stock units and stock options of Ayala, subject to the terms of the merger agreement. No fractional shares will be issued in connection with the merger and Advaxis will pay cash in lieu of any such fractional shares. The merger is intended to qualify for U.S. federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended.
Consummation of the merger is subject to certain closing conditions, including, among other things, approval by the stockholders of Ayala. At the closing of the merger, Ayala will be delisted from The Nasdaq Global Market. The combined company's common stock is expected to begin trading on the OTCQX at the effective time of the merger, subject to Advaxis' planned efforts to have the stock of the combined company listed on Nasdaq, as to which no assurances can be made.

Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement in All-Stock Deal

IPOs

Advaxis Says Applied To List Common Stock On NASDAQ Under Symbol 'ADXS'

Events

ACET

ACLX

BGNE

CGEM

GRTX

PVCT

Several Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Meeting Jun. 3-7: Provectus, Advaxis, Adicet Bio, Cullinan Oncology, Galera, BeiGene, Arcellx, PDS Biotech, Tempest, Karyopharm

Updated data show a second partial response in Part B 
&nbsp;
Overall response rate of&nbsp;15.4%&nbsp;and disease control rate of&nbsp;46%&nbsp;in Part B with durable clinical benefit in patients with prior disease progression
Preliminary data show disease control rate of&nbsp;67%&nbsp;in first 3 patients in Part C, with ADXS-503 being dosed in combination with pembrolizumab in first line
MONMOUTH JUNCTION, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) --&nbsp;Advaxis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXS#NASDAQ">ADXS</a>), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced updated data from the Company&#39;s ongoing Phase 1/2 study evaluating ADXS-503 in combination with KEYTRUDA&reg;. ADXS-503 is the first drug construct from the ADXS-HOT off-the-shelf, cancer-type specific, immunotherapy program which leverages Advaxis&#39; proprietary&nbsp;Lm&nbsp;technology platform to target hotspot mutations that commonly occur in specific cancer types as well as other proprietary, tumor-associated antigens.
&quot;NSCLC patients resistant to PD-1/-L1 checkpoint inhibitors (CPIs) have limited treatment options. Current treatment guidelines allow for CPI re-challenge but the&nbsp;overall response rate (ORR) seen with this approach is below&nbsp;10%&nbsp;and disease control rate (DCR) of up to&nbsp;45%. Thus, it is encouraging to report that in Part B of the study, the documented ORR has now increased to 15.4 % and DCR has reached&nbsp;46%&nbsp;in the first 13&nbsp;evaluable patients treated with ADXS-503 as an add-on therapy at progression with pembrolizumab,&quot; said Dr. Jonathan W. Goldman, Associate Professor of UCLA Hematology and Oncology, Associate Director of Drug Development and Director of Clinical Trials in Thoracic Oncology at UCLA Medical Center in Santa Monica, California. &quot;These results now include a second additional patient with a partial response and 4 patients with stable disease. The durable nature of disease control is also encouraging and includes two patients with ongoing partial responses for 702 and 189 days, and three patients with stable disease&nbsp;sustained for&nbsp;448, 175 and 117 days.&quot;
Dr. Goldman continued, &quot;If the addition of ADXS-503 to patients progressing on pembrolizumab couldachieve a durable response rate at or above&nbsp;20%, with minimal added toxicity, this combination could become a new therapeutic option for this underserved patient population. We look forward to completing the enrollment of a total of 18 patients in Stage 1 of Part B.&quot;
Dr. Andres A. Gutierrez, Chief Medical Officer of Advaxis, said, &quot;The enrollment of Part C of the study, evaluating NSCLC patients treated in first line with ADXS-503 in combination with pembrolizumab, has also started. Given the median progression free survival (PFS) achieved with CPIs alone in first line NSCLC is 7-10 months, and the encouraging results from Part B in this study, it is expected that the addition of ADXS-503 to pembrolizumab may achieve meaningful improvements in PFS above standard of care with a target of greater than or equal to 9 months. Three patients have thus far been evaluated showing a disease control rate of&nbsp;67%, with two patients sustaining stable disease for 332 and 94 days. As expected, the combination therapy has been well tolerated with mild and transient flu-like syndrome a few hours after the infusion of the drugs but without increasing the frequency of immune-related adverse events.&quot;
Ken Berlin, Chief Executive Officer of Advaxis, said, &quot;Major milestones for the ADXS-503 trial in the second half of 2022 include updated clinical and immunogenicity data for all patients in Stage 1 in Part B and from up to 10 patients in Part C. Also, initial clinical and immunogenicity data from the ADXS-504 trial in early prostate cancer are expected to be reported in the second half of this year.&quot;
Key Updates and Future Data Read-outs:
<ul>
<li>In Part B of the study, 14 patients have been treated and 13 are evaluable with ADXS-503 as an add on therapy to patients failing pembrolizumab as last therapy with all of them evaluable for safety and efficacy</li>
</ul>
<ul>
<li>Combination therapy was well tolerated with no dose-limiting-toxicity (DLT) or added toxicity of the two drugs. Grade 1 and 2, transient and reversible events included chills, fever, fatigue, in approximately half of the patients</li>
</ul>
<ul>
<li>The ORR was&nbsp;15.4%&nbsp;(2/13) and DCR was&nbsp;46%&nbsp;(6/13)</li>
</ul>
<ul>
<li>Clinical benefit was durable, with two partial responses (PR) sustained for 702 and 189 days, respectively, and 3 patients with stable disease (SD), sustained for 448, 175 and 117 days. Another patient with stable disease is still under evaluation 
	&nbsp;</li>
<li>Available data demonstrate that patients who achieve clinical benefit include those with PD-L1 expression &ge;50%, secondary resistance disease to pembrolizumab and those who show proliferation and/or activation of NK and CD8+ T cells within the first weeks of therapy</li>
<li>Additional translational studies, including flow cytometry, ELISPOT, cytokines/chemokine levels, mutational analysis, MSI TMB and cfDNA and their clinical correlates, will be presented at an upcoming medical meeting</li>
</ul>
<ul>
<li>In Part C of the study, 3 patients with newly diagnosed NSCLC have been treated with ADXS-503 plus pembrolizumab. Treatment has been well tolerated and disease control rate thus far is&nbsp;67%, with two patients sustaining stable disease for 332 and 94 days.</li>
</ul>
<ul>
<li>Enrollment in Part B and Part C of the ongoing study will continue to further evaluate the clinical benefit and immune effects of adding on ADXS-503 to patients progressing on pembrolizumab 
	&nbsp;</li>
</ul>
The Phase 1/2 clinical trial of ADXS-503 is seeking to establish the recommended dose, safety, tolerability and clinical activity of ADXS-503 administered alone and in combination with a KEYTRUDA&reg; in approximately 50 patients with NSCLC, in at least five sites across the U.S. The two dose levels with monotherapy in Part A, (1 X108&nbsp;and 5 X108&nbsp;CFU) have been completed. Part B with ADXS-503 (1 X108&nbsp;CFU) in combination with KEYTRUDA&reg; is currently enrolling its efficacy expansion for up to 18 patients at dose level 1 (1 X108&nbsp;CFU + KEYTRUDA&reg;) with the potential to proceed to dose level 2 (5 X108&nbsp;CFU + KEYTRUDA&reg;) at a later date. Part C of this ADXS-503 trial evaluating ADXS-503 in combination with KEYTRUDA&reg; (1 X108&nbsp;CFU + KEYTRUDA&reg;) as a first line treatment for patients with NSCLC with PD-L1 expression &ge;&nbsp;1%&nbsp;or who are unfit for chemotherapy, is currently enrolling patients.

Advaxis Highlights Presentation Of Updated Clinical Data From Ongoing Phase 1/2 Trial Of ADXS-503 In NSCLC And Upcoming Milestones

<h3>Gainers</h3>
<ul>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) shares rose 29.91% to $2.91 during Wednesday's after-market session. At the close, BioCardia's trading volume reached 793.9K shares. This is 471.05% of its average volume over the last 100 days. The company's market cap stands at $49.0 million. </li>
<li>AnPac Bio-Medical Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANPC#NASDAQ">ANPC</a>) shares moved upwards by 8.91% to $1.1. The market value of their outstanding shares is at $19.5 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares rose 5.19% to $2.43. The market value of their outstanding shares is at $85.8 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock moved upwards by 4.71% to $2.0. The company's market cap stands at $16.6 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares increased by 4.45% to $0.64. The market value of their outstanding shares is at $20.7 million. </li>
<li>Genfit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) shares rose 4.26% to $5.87. The company's market cap stands at $268.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Advaxis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXS#NASDAQ">ADXS</a>) shares declined by 30.0% to $0.17 during Wednesday's after-market session. Advaxis's trading volume hit 3.9 million shares by close, accounting for 87.55% of its average volume over the last 100 days. The market value of their outstanding shares is at $24.4 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock fell 7.65% to $4.47. Trading volume for this security closed at 365.8K, accounting for 6.42% of its average full-day volume over the last 100 days. The company's market cap stands at $108.4 million. </li>
<li>Roivant Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>) shares declined by 5.15% to $11.24. The market value of their outstanding shares is at $7.6 billion. </li>
<li>BiondVax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVXV#NASDAQ">BVXV</a>) shares decreased by 4.46% to $2.79. At the close, BiondVax Pharmaceuticals's trading volume reached 359.4K shares. This is 459.89% of its average volume over the last 100 days. The company's market cap stands at $39.9 million. </li>
<li>Midatech Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTP#NASDAQ">MTP</a>) shares fell 4.1% to $1.17. The company's market cap stands at $14.8 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) shares fell 3.54% to $5.18. The market value of their outstanding shares is at $18.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANPC

BCDA

BRTX

BSGM

BVXV

ENSC

EVOK

GNFT

QNRX

ROIV

12 Health Care Stocks Moving In Wednesday's After-Market Session

Stockholders approved Proposal 1 in support of Biosight merger
Proposal 2 reverse stock split, a condition for completing the merger of Advaxis and Biosight, was not approved 
MONMOUTH JUNCTION, N.J., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXS#NASDAQ">ADXS</a>), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that following the conclusion of its second reconvened special meeting of stockholders on December 16, 2021, it plans to continue to explore additional options to maximize stockholder value. The Company&rsquo;s Proposal 2 to authorize a reverse stock split, a condition to consummating the Company&rsquo;s agreed upon merger with Biosight, was not approved at the meeting.
Voting results at the first reconvened special meeting of stockholders held on December 7, 2021 signaled support for the Biosight merger through the approval of Proposal 1, which related to the issuance of shares of common stock of Advaxis to shareholders of Biosight pursuant to the terms of the merger agreement, as well as the change of control resulting from the merger (&ldquo;merger proposal&rdquo;). The merger proposal received the requisite stockholder votes by a clear majority of votes cast and, as a result, has passed.
While Proposal 2, the reverse stock split proposal, also received the support of a clear majority of the votes cast, this proposal had a higher vote threshold as a matter of law, requiring the support of the majority of total shares outstanding.&nbsp; Approval of a reverse stock split as contemplated by Proposal 2 is a condition for completing the merger of Advaxis and Biosight. The Company intends to provide an update on these matters in the near future.

Markets

Advaxis Reports Will Explore Added Options To Maximize Shareholder Value; Shareholders Approved Proposal 1, Reverse Split Proposal Not Approved

<h3>Gainers</h3>
<ul>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares increased by 16.75% to $2.23 during Friday's pre-market session. The market value of their outstanding shares is at $7.8 million. </li>
<li>VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) stock moved upwards by 14.49% to $1.58. The market value of their outstanding shares is at $84.5 million. </li>
<li>Infinity Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INFI#NASDAQ">INFI</a>) shares rose 14.18% to $2.65. The market value of their outstanding shares is at $235.8 million. </li>
<li>Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) shares rose 11.63% to $2.59. The market value of their outstanding shares is at $153.6 million. </li>
<li>First Wave BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWBI#NASDAQ">FWBI</a>) shares rose 7.27% to $1.77. The market value of their outstanding shares is at $26.1 million. </li>
<li>Advaxis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXS#NASDAQ">ADXS</a>) stock rose 6.38% to $0.37. The company's market cap stands at $53.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) stock fell 9.34% to $246.81 during Friday's pre-market session. The market value of their outstanding shares is at $100.0 billion. </li>
<li>Midatech Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTP#NASDAQ">MTP</a>) stock decreased by 8.09% to $1.25. The market value of their outstanding shares is at $15.8 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock declined by 7.05% to $4.62. The company's market cap stands at $112.0 million. </li>
<li>ThermoGenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) shares decreased by 6.49% to $1.13. The company's market cap stands at $13.4 million. </li>
<li>MorphoSys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOR#NASDAQ">MOR</a>) stock declined by 4.06% to $9.46. The company's market cap stands at $1.2 billion. </li>
<li>Lexaria Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXX#NASDAQ">LEXX</a>) shares declined by 3.82% to $4.79. The company's market cap stands at $27.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FWBI

GALT

INFI

LEXX

Morgan Stanley Capital Protected Notes for S&P 500 Index

MRNA

RSLS

THMO

VYNE

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Lannett (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCI#NYSE">LCI</a>) shares rose 11.61% to $1.73 during Tuesday's after-market session. The market value of their outstanding shares is at $74.3 million. </li>
<li>Zosano Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZSAN#NASDAQ">ZSAN</a>) shares increased by 8.33% to $0.65. Trading volume for this security closed at 154.6K, accounting for 7.11% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $76.9 million. </li>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) stock increased by 6.59% to $14.07. At the close, Gritstone Bio's trading volume reached 358.1K shares. This is 34.79% of its average volume over the last 100 days. The company's market cap stands at $956.5 million. </li>
<li>Brookdale Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKD#NYSE">BKD</a>) shares rose 5.28% to $6.18. Today's trading volume for this security ended up closing at 923.8K shares, which is 35.04 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $1.1 billion. </li>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) shares rose 4.79% to $7.0. At the close, NRX Pharmaceuticals's trading volume reached 96.1K shares. This is 2.33% of its average volume over the last 100 days. The market value of their outstanding shares is at $411.6 million. </li>
<li>SINTX Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares increased by 4.6% to $0.93. The company's market cap stands at $22.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock decreased by 7.31% to $17.12 during Tuesday's after-market session. This security traded at a volume of 61.6K shares come close, making up 1.42% of its average volume over the last 100 days. The market value of their outstanding shares is at $119.2 million. </li>
<li>BeyondSpring (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYSI#NASDAQ">BYSI</a>) stock fell 6.03% to $12.0. BeyondSpring's trading volume hit 410.0K shares by close, accounting for 39.11% of its average volume over the last 100 days. The company's market cap stands at $469.3 million. </li>
<li>Immunogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMGN#NASDAQ">IMGN</a>) shares fell 5.84% to $5.81. At the close, Immunogen's trading volume reached 1.0 million shares. This is 65.24% of its average volume over the last 100 days. The company's market cap stands at $1.1 billion. </li>
<li>GBS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBS#NASDAQ">GBS</a>) stock fell 4.55% to $1.89. Trading volume for this security closed at 95.8K, accounting for 12.64% of its average full-day volume over the last 100 days. The company's market cap stands at $28.1 million. </li>
<li>Eloxx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELOX#NASDAQ">ELOX</a>) shares declined by 4.55% to $0.71. The company's market cap stands at $61.2 million. </li>
<li>Advaxis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXS#NASDAQ">ADXS</a>) stock declined by 4.36% to $0.35. Trading volume for this security closed at 158.1K, accounting for 2.32% of its average full-day volume over the last 100 days. The company's market cap stands at $51.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BYSI

ELOX

GRTS

IMGN

ISPC

NRXP

SINT

ZSAN

12 Health Care Stocks Moving In Tuesday's After-Market Session

Advaxis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXS#NASDAQ">ADXS</a>), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today issued the following statement to stockholders:
Dear Fellow Advaxis Stockholders:
I am writing to provide you with additional information and resources regarding the Company&#39;s proposed merger with Biosight.&nbsp; We believe that the proposed Biosight transaction can generate significant value for Advaxis stockholders.&nbsp; The combined company will be better capitalized and well-positioned to advance a broader portfolio of drug candidates aimed at addressing both liquid and solid tumors.&nbsp; The closing of the transaction is contingent upon, among other things, the approval of Advaxis&#39; stockholders at the Special Meeting initially held on November 16, 2021 and adjourned to December 7, 2021.
Please go to the&nbsp;<a href="https://www.globenewswire.com/Tracker?data=6Q9v2oEgFi2ZaWwn0iLC3aGanwvOcAaxzZPIJ1Fa7kCEtAYtIh52w1LS04CNU0qp7tM1O03FGlaMBWOvv_VPkQ==" target="_blank">Advaxis website</a>&nbsp;to watch the video entitled &quot;Message About Proxy Proposal 2&quot; we prepared to provide you with some additional information about the Biosight transaction and proxy proposal 2 to help inform your voting decision.&nbsp;
In addition, two leading independent proxy advisory firms, Institutional Shareholder Services (ISS) and Glass Lewis &amp; Co., have recommended that stockholders vote &quot;FOR&quot; all of the proposals at the special meeting. We strongly urge you to vote today in support of the merger and related proposals.
How to Vote
To vote, or if you have already voted and would like to change your vote, or if you have any questions or need assistance voting your shares, please call the firm assisting us with the solicitation of proxies:
Kingsdale Advisors
1-888-518-1560 (toll free)
<a href="https://www.globenewswire.com/Tracker?data=Kccw7zL27Xd32Ru7DY8QqdyQbN-rMUMgYhB0Y8RPEfWpMEPpPduEnBSPzVJTOqcgnrprJoi6JFWelJTsRneDPc7tKcaq81S71ATIA3i8frtqAJDwBiYsVeqMSOtUTVBr" target="_blank">contactus@kingsdaleadvisors.com</a>
Thank you for attention to this matter.
Kenneth A. Berlin
President and Chief Executive Officer
and Interim Chief Financial Officer

Advaxis Issues Letter, Second Video Message To Stockholders Regarding Upcoming Special Meeting

View patent <a href="https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&amp;r=6280&amp;f=G&amp;l=50&amp;d=PTXT&amp;p=126&amp;S1=20211123&amp;OS=20211123&amp;RS=20211123"> here</a>

Advaxis Granted U.S. Patent #11,179,339 'Compositions and methods for lyophilization of bacteria or listeria strains'

Advaxis, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXS#NASDAQ">ADXS</a>), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today issued the following statement to stockholders: 
&nbsp;
Dear Fellow Advaxis Stockholders:
We have prepared this summary to highlight the starkly different scenarios Advaxis&#39; stockholders face depending on the outcome of the voting at the Company&#39;s special meeting of stockholders relating to its proposed merger with Biosight, which was initially held on November 16, 2021 and has been adjourned to December 7, 2021. In short, we believe consummation of the Biosight merger will result in a substantially more favorable outcome for Advaxis stockholders than the alternative.&nbsp;&nbsp;
In our view, the merger between Biosight and Advaxis represents a significant opportunity for Advaxis stockholders to participate in a transformational transaction that establishes a stronger biopharma franchise with multiple opportunities ahead.&nbsp;&nbsp; Earlier this month some of Biosight&#39;s largest shareholders and other institutional investors have demonstrated their support for the merger by subscribing to a critical round of investment &ndash; but this commitment is contingent upon Advaxis stockholders approving the merger proposals to allow for the consummation of the transaction. To reiterate, this funding will not occur unless the merger is approved and consummated.&nbsp;&nbsp;
When the following key points are properly considered, we believe the choice is an easy one.
We believe the impact to Advaxis stockholders is drastically different if the merger with Biosight is consummated versus it not being consummated as you can see from the following:
1)&nbsp;&nbsp;&nbsp;Approval&nbsp;of the merger proposals and consummation of the transaction: 
&nbsp;
<ul>
<li>Provides stockholders with an ownership interest in a company with a broader and more diversified pipeline of drug candidates in terms of:

	&nbsp;
<ul>
<li>Diversity: More shots on goal</li>
<li>Time to market: Biosight&#39;s drug candidate is at a more advanced stage of development which brings it closer to potential regulatory approval</li>
<li>Risk Profile: Safety and efficacy data of Biosight&#39;s drug in 91 patients treated has been encouraging to date which we believe increases the chances of regulatory approval</li>
</ul>
</li>
</ul>
<ul>
<li>Enables the Company to maintain its Nasdaq listing, preserving greater liquidity for all stockholders and enhances opportunity for future capital raising and institutional investment

	&nbsp;</li>
<li>Creates a better capitalized company with&nbsp;$21 million&nbsp;of recently announced new financing from institutional investors to advance new drug development contingent on the merger closing 
	&nbsp;</li>
</ul>
2)&nbsp;&nbsp;&nbsp;If the merger proposals are NOT approved: 
&nbsp;
<ul>
<li>We believe Advaxis will be in a materially weaker position

	&nbsp;</li>
<li>Limits the Company&#39;s drug development efforts, relegating its pipeline to an early stage, less diverse and riskier prospects

	&nbsp;</li>
<li>Substantially reduces stockholder liquidity through imminent delisting with no identified near-term catalysts of significance to regain listing compliance

	&nbsp;</li>
<li>Results in a financially less stable company with diminished capabilities to raise future capital required not only to continue drug development but to simply remain solvent 
	&nbsp;</li>
</ul>
<table>
<tbody>
<tr>
<td>Impact</td>
<td>If Merger&nbsp;IS&nbsp;Consummated</td>
<td>If Merger is&nbsp;NOT&nbsp;consummated</td>
</tr>
<tr>
<td>Corporate Stability &amp; Upside Potential</td>
<td>Merged company is&nbsp;stronger&nbsp;than a stand-alone Advaxis and has a&nbsp;broader and more diverse pipeline&nbsp;of drug candidates in terms of:

			&nbsp;
<ul>
<li>Diversity: More shots on goal</li>
</ul>
<ul>
<li>Development: More advanced stage of development of Biosight&#39;s drug candidate brings it closer to potential regulatory approval</li>
</ul>
<ul>
<li>Risk Profile: Encouraging safety and efficacy data of Biosight&#39;s drug in 91 patients treated to date increase the chances of regulatory approval and mitigate risk</li>
</ul>
</td>
<td>A stand-alone Advaxis would be left in a&nbsp;materially weaker&nbsp;position with a limited, early-stage pipeline that is less diverse and&nbsp;significantly riskier</td>
</tr>
<tr>
<td>Balance Sheet</td>
<td>Creates a better capitalized company with&nbsp;$21 million&nbsp;of recently announced new PIPE financing from institutional investors to advance new drug development contingent on the merger closing</td>
<td>A stand-alone Advaxis would be&nbsp;financially less stable&nbsp;with less cash ($21 million&nbsp;PIPE, contingent on the merger, disappears if voted against) and a diminished opportunity to raise future capital, adversely impacting ability to continue drug development and to simply remain solvent</td>
</tr>
<tr>
<td>Stockholder Liquidity</td>
<td>Enables the company to maintain its Nasdaq listing, preserving&nbsp;greater liquidity&nbsp;for all stockholders and enhances opportunity for capital raising including follow-on&nbsp;institutional investment</td>
<td>Substantially reduces stockholder liquidity through&nbsp;imminent delisting&nbsp;with no near-term catalysts of significance to regain listing compliance</td>
</tr>
</tbody>
</table>

&nbsp;
The Special Meeting, initially held on November 16, 2021, has been adjourned to December 7, 2021 at 10:00 AM Eastern Time unless postponed or adjourned to a later date, in order to obtain the stockholder approvals necessary to complete the merger and related matters. Advaxis stockholders will be able to attend and participate in the Advaxis special meeting online by visiting&nbsp;<a href="http://www.virtualshareholdermeeting.com/ADXS2021SM">www.virtualshareholdermeeting.com/ADXS2021SM</a>&nbsp;where they will be able to listen to the meeting live, submit questions and vote.

Advaxis, Inc. Issues Letter to Stockholders

Advaxis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXS#NASDAQ">ADXS</a>), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that leading independent proxy advisory firm, Glass Lewis &amp; Co. (Glass Lewis), joins Institutional Shareholder Services (ISS) in recommending that Advaxis stockholders vote &quot;FOR&quot; the stockholder proposals relating to the Company&#39;s proposed merger with Biosight. 
&nbsp;
In its report dated November 11, 2021, Glass Lewis stated1:
<ul>
<li>We believe the strategic rationale for the proposed transaction is generally reasonable from the perspective of Advaxis shareholders.

	&nbsp;</li>
<li>We find that the analyses presented by the advisor are reasonable and contain adequate disclosure. In particular, we note from the advisor&#39;s Comparable Initial Public Offerings Analysis that the implied value of the proposed consideration for Biosight&nbsp;($218 million)&nbsp;falls within the fair value range derived by the advisor using pre-money equity values observed in seven IPOs involving Phase 2 companies without completing a crossover financing ($187 million&nbsp;to&nbsp;$406 million) and well below the range derived using equity values observed in 12 IPOs involving Phase 2 companies with a focus on oncology ($648 million&nbsp;to&nbsp;$819 million).

	&nbsp;</li>
<li>Overall, we see no cause for significant shareholder concern with the strategic rationale or financial aspects of the proposed transaction, which would allow Advaxis shareholders to benefit from the development pipeline and stronger financial position of the combined company.

	&nbsp;</li>
<li>Based on the forgoing factors and the support of the board, we believe the proposed transaction is in the best interests of shareholders. 
	&nbsp;</li>
</ul>
Commenting on the reports, Kenneth A. Berlin, President, Chief Executive Officer and Interim Chief Financial Officer of Advaxis, said, &quot;We are pleased that both Glass Lewis and ISS support our proposed combination with Biosight and recommend that Advaxis shareholders vote &quot;FOR&quot; the stockholder proposals relating to the merger. Our Board, which unanimously approved this transaction, is confident that merging with Biosight will create a well capitalized and better-positioned Company to advance a broader portfolio of drug candidates aimed at addressing both liquid and solid tumors. We strongly urge all Advaxis stockholders to follow the recommendations of ISS and Glass Lewis and vote &quot;FOR&quot; the shareholder proposals relating to the proposed combination with Biosight.&quot;
The Special Meeting, initially held on November 16, 2021, has been adjourned to December 7, 2021 at 10:00 AM Eastern Time unless postponed or adjourned to a later date, in order to obtain the stockholder approvals necessary to complete the merger and related matters. Advaxis stockholders will be able to attend and participate in the Advaxis special meeting online by visiting&nbsp;<a href="https://www.globenewswire.com/Tracker?data=9ILe7I_oV7V9WHXl73UJMzdffsh6_DrVppTu2GhXempJYV5y9Wkk3R95bmsLtqw6KX3_U6xQec3SOh-F1q0wP41js4dUaCQXPL0F_pmEF2RzB9wvAkuR4n1ju8_xGqD-vSs8SWj28a0DbUKfl8NDlHNG53QIM74edwehN0F_icA=" target="_blank">www.virtualshareholdermeeting.com/ADXS2021SM</a>&nbsp;where they will be able to listen to the meeting live, submit questions and vote.

Independent Proxy Advisory Firm Glass Lewis Joins ISS In Recommending Advaxis Stockholders Vote "FOR" Proposed Merger With Biosight

MSFT

NVDA

PLTR

PSFE

SNDL

TSLA

WISH

Top 10 WallStreetBets Stock Mentions In Pre-Market Session for Nov.12, 2021: SNDL, TSLA, GME, MSFT, NVDA, PLTR, PSFE, ADXS, AMC, WISH

<h3>Gainers</h3>
<ul>
<li>FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) stock moved upwards by 4.99% to $10.73 during Thursday's after-market session. The company's market cap stands at $993.8 million. </li>
<li>Advaxis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXS#NASDAQ">ADXS</a>) stock moved upwards by 3.54% to $0.54. Today's trading volume for this security ended up closing at 207.7K shares, which is 2.5 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $78.6 million. </li>
<li>Kala Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) shares increased by 3.43% to $2.71. The market value of their outstanding shares is at $176.0 million. </li>
<li>Xenetic Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIO#NASDAQ">XBIO</a>) shares moved upwards by 3.41% to $2.12. The market value of their outstanding shares is at $20.5 million. </li>
<li>Cue Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) stock rose 3.13% to $12.18. The company's market cap stands at $1.7 billion. </li>
<li>Mereo BioPharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) shares rose 2.89% to $2.49. The company's market cap stands at $271.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alector (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) stock declined by 5.7% to $21.52 during Thursday's after-market session. Trading volume for this security closed at 64.3K, accounting for 4.11% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.7 billion. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares fell 2.43% to $22.1. The market value of their outstanding shares is at $279.4 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock fell 2.43% to $2.01. The company's market cap stands at $48.4 million. </li>
<li>Evofem Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVFM#NASDAQ">EVFM</a>) stock declined by 2.39% to $0.72. The market value of their outstanding shares is at $111.9 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock decreased by 2.34% to $3.77. The company's market cap stands at $58.0 million. </li>
<li>ASLAN Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLN#NASDAQ">ASLN</a>) shares decreased by 2.25% to $1.74. The company's market cap stands at $121.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>

AEMD

ALEC

ASLN

EVFM

FGEN

HLTH

KALA

MREO

NAOV

XBIO

12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers
&nbsp;
<ul>
<li>Stealth BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITO#NASDAQ">MITO</a>) stock rose 3.59% to $1.44 during Thursday&#39;s after-market session. The market value of their outstanding shares is at $82.9 million.</li>

<li>Advaxis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXS#NASDAQ">ADXS</a>) shares rose 2.8% to $0.54. The company&#39;s market cap stands at $78.3 million. The company&#39;s, Q3 earnings came out 4 days ago.</li>

<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) stock increased by 2.16% to $12.29. The market value of their outstanding shares is at $294.3 million.</li>

<li>Teligent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLGT#NASDAQ">TLGT</a>) shares rose 1.93% to $0.39. The market value of their outstanding shares is at $36.1 million.</li>

<li>InVivo Therapeutics Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVIV#NASDAQ">NVIV</a>) shares moved upwards by 1.74% to $0.62. The market value of their outstanding shares is at $21.2 million.</li>

<li>Calithera Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALA#NASDAQ">CALA</a>) shares increased by 1.46% to $2.08. The company&#39;s market cap stands at $154.1 million.</li>
	&nbsp;
</ul>
&nbsp;
&nbsp;
<h3>Losers</h3>
&nbsp;
&nbsp;
<ul>
<li>Champions Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) shares decreased by 6.0% to $10.03 during Thursday&#39;s after-market session. The market value of their outstanding shares is at $134.6 million. The company&#39;s, Q1 earnings came out 3 days ago.</li>

<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares decreased by 5.25% to $12.83. Trading volume for this security closed at 175.0K, accounting for 24.13% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $634.4 million.</li>

<li>Checkpoint Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CKPT#NASDAQ">CKPT</a>) stock decreased by 4.9% to $3.11. The company&#39;s market cap stands at $257.3 million.</li>

<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares decreased by 4.41% to $11.07. The company&#39;s market cap stands at $59.8 million.</li>

<li>Pieris Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIRS#NASDAQ">PIRS</a>) stock declined by 4.0% to $5.53. The company&#39;s market cap stands at $368.9 million.</li>

<li>ClearPoint Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPT#NASDAQ">CLPT</a>) stock decreased by 3.55% to $18.25. The company&#39;s market cap stands at $408.1 million.</li>
	&nbsp;
</ul>
&nbsp;
&nbsp;

CALA

CKPT

CLPT

CSBR

INDP

MITO

NVIV

PIRS

TLGT

XAIR

Press Releases

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline

OSTX

AYALA PHARMACEUTICALS INC by Ayala Pharmaceuticals, Inc.

Ayala Pharmaceuticals

Comments

Ayala Pharmaceuticals

Ayala Pharmaceuticals (ADXS) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO